Immunoprecise Antibodies Ltd (IPA) — Cash Flow Reinvestment Rate

Latest as of October 2020: 3.25x

Immunoprecise Antibodies Ltd (IPA) has a Cash Flow Reinvestment Rate of 3.25x as of October 2020, reinvesting $1.43 Million (capex $715.21K plus investments $-715.21K) from operating cash flow of $440.23K. See Immunoprecise Antibodies Ltd (IPA) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

3.25x
(Capex + Investments) / Operating CF

Total Reinvested

$1.43 Million
Capex + Investments

Operating Cash Flow

$440.23K
USD

Capital Expenditures

$715.21K
USD

Immunoprecise Antibodies Ltd Cash Flow Reinvestment Rate (2016–2016)

Historical reinvestment intensity for Immunoprecise Antibodies Ltd across 1 annual periods. For the full cash flow conversion analysis, see how efficiently does Immunoprecise Antibodies Ltd generate cash.

Annual Cash Flow Reinvestment Rate for Immunoprecise Antibodies Ltd (2016–2016)

Year-by-year capital reinvestment analysis for Immunoprecise Antibodies Ltd. See Immunoprecise Antibodies Ltd (IPA) flexibility index to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2016 0.06x $17.48K $284.09K $17.48K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow